RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
PYC Therapeutics Stock

PYC Therapeutics Revenue 2024

PYC Therapeutics Revenue

22.86 M AUD

Ticker

PYC.AX

ISIN

AU000000PYC7

WKN

A0D8ZY

In 2024, PYC Therapeutics's sales reached 22.86 M AUD, a 43.85% difference from the 15.89 M AUD sales recorded in the previous year.

The PYC Therapeutics Revenue history

YEARREVENUE (undefined AUD)GROSS MARGIN (%)
2028e6.73-27,30
2027e20.2-9,09
2026e31.06-5,92
2025e8.84-20,79
202422.86-8,04
202315.89-11,56
202216.07-11,43
20213.18-57,72
20202.6-70,59
20190-734868,00
20180.05-2633,78
20172.7664,02
2016--
20150.8128,54
20140.717,14
20130.7122,54
20121.9268,23
20112.3678,81
20100.6-35,00
20091.2839,84
20080.8861,36
20070.9471,28
20060.4971,43
20050.16-1148,23

PYC Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into PYC Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PYC Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PYC Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of PYC Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into PYC Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing PYC Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PYC Therapeutics’s growth potential.

PYC Therapeutics Revenue, EBIT and net profit per share

DatePYC Therapeutics RevenuePYC Therapeutics EBITPYC Therapeutics Net Income
2028e6.73 M AUD-100.73 M AUD-89.88 M AUD
2027e20.2 M AUD-67.29 M AUD-44.72 M AUD
2026e31.06 M AUD-23.65 M AUD-21.5 M AUD
2025e8.84 M AUD-42.55 M AUD-40.51 M AUD
202422.86 M AUD-37.57 M AUD-37.73 M AUD
202315.89 M AUD-23.28 M AUD-22.79 M AUD
202216.07 M AUD-14.26 M AUD-13.86 M AUD
20213.18 M AUD-18.65 M AUD-17.77 M AUD
20202.6 M AUD-7.1 M AUD-6.82 M AUD
2019250 AUD-7.1 M AUD-4.08 M AUD
201848,460 AUD-9.72 M AUD-7.43 M AUD
20172.76 M AUD-4.25 M AUD-1.95 M AUD
20160 AUD-6.23 M AUD-3.98 M AUD
2015813,380 AUD-5.05 M AUD-2.99 M AUD
2014700,000 AUD-5.18 M AUD-3.26 M AUD
2013710,000 AUD-5.32 M AUD-3.44 M AUD
20121.92 M AUD-3.9 M AUD-3.9 M AUD
20112.36 M AUD-3.61 M AUD-3.61 M AUD
2010600,000 AUD-4.57 M AUD-4.57 M AUD
20091.28 M AUD-3.6 M AUD-4.49 M AUD
2008880,000 AUD-4.48 M AUD-4.48 M AUD
2007940,000 AUD-3.89 M AUD-3.89 M AUD
2006490,000 AUD-4.28 M AUD-3.99 M AUD
2005160,000 AUD-1.59 M AUD-1.59 M AUD

PYC Therapeutics stock margins

The PYC Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PYC Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PYC Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the PYC Therapeutics's sales revenue. A higher gross margin percentage indicates that the PYC Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the PYC Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the PYC Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PYC Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PYC Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PYC Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

PYC Therapeutics Margin History

PYC Therapeutics Gross marginPYC Therapeutics Profit marginPYC Therapeutics EBIT marginPYC Therapeutics Profit margin
2028e-734,867.97 %-1,497.01 %-1,335.75 %
2027e-734,867.97 %-333.12 %-221.36 %
2026e-734,867.97 %-76.15 %-69.22 %
2025e-734,867.97 %-481.45 %-458.42 %
2024-734,867.97 %-164.37 %-165.06 %
2023-734,867.97 %-146.49 %-143.43 %
2022-734,867.97 %-88.76 %-86.28 %
2021-734,867.97 %-585.95 %-558.23 %
2020-734,867.97 %-272.76 %-262.12 %
2019-734,867.97 %-2.84 M %-1.63 M %
2018-2,633.78 %-20,057.14 %-15,340.49 %
201764.02 %-154.12 %-70.68 %
2016-734,867.97 %0 %0 %
201528.54 %-620.75 %-367.78 %
201417.14 %-740 %-465.71 %
201322.54 %-749.3 %-484.51 %
201268.23 %-203.13 %-203.13 %
201178.81 %-152.97 %-152.97 %
2010-35 %-761.67 %-761.67 %
200939.84 %-281.25 %-350.78 %
200861.36 %-509.09 %-509.09 %
200771.28 %-413.83 %-413.83 %
200671.43 %-873.47 %-814.29 %
2005-734,867.97 %-993.75 %-993.75 %

PYC Therapeutics Aktienanalyse

What does PYC Therapeutics do?

PYC Therapeutics Ltd is a biopharmaceutical company based in Sydney, Australia. The company was founded in 2017 by experienced pharmaceutical and biotech managers and currently employs over 40 employees. The history of PYC Therapeutics began with the development of a novel therapy platform called "PCytTM", which is based on the use of artificial proteins. These proteins can enhance the uptake of drugs into cells, thereby increasing the effectiveness of various medications. In 2018, PYC Therapeutics achieved a significant milestone by being included in the prestigious Accelerating Commercialisation program of the Australian government. PYC Therapeutics' business model focuses on the research and development of innovative cancer therapies and rare genetic diseases. The company strives to focus on diseases for which there is currently no effective treatment. This is intended to be achieved through partnerships, licensing, and potentially through the acquisition of companies and technologies. PYC Therapeutics shapes its processes through collaboration with experts in the fields of medicine, pharmacy, biotechnology, and chemistry. The divisions of PYC Therapeutics can be divided into the following areas of activity: drug development, platform technology, partnerships, and research and development. Under drug development, PYC Therapeutics understands the actual production of new cancer therapeutics and medications for the treatment of rare genetic diseases. The company relies on its internal research and also utilizes in-licensed technologies and acquisitions to develop novel drugs. Platform technology is a key success factor for PYC Therapeutics. The company has developed a highly effective method with PCytTM to optimize drug transport. This can significantly enhance the efficacy of medications. This technology has the potential to revolutionize the treatment of many diseases. Partnerships are an important part of PYC Therapeutics' business model. The company focuses on long-term collaborations with large pharmaceutical and biotech companies. This cooperation is intended to accelerate the development, approval, and commercialization of new medications. Research and development form the core of PYC Therapeutics' business model. The company invests significantly in the exploration of new therapeutics for cancer and rare genetic diseases. Since its inception, the company has continuously expanded its development platform and has become a key player in the industry. One of PYC Therapeutics' most important pipeline products is "PYC-06". PYC-06 is a medication developed for the treatment of acute myeloid leukemia (AML). The therapy aims to enhance the potential of chemotherapeutics by using PCytTM. The initial results of clinical studies show very promising results. Overall, PYC Therapeutics is an important player in the field of innovative cancer care and the treatment of rare genetic diseases. The company has a strong pipeline of novel therapeutics based on its PCytTM technology. PYC Therapeutics strives to improve the treatment of cancer and rare diseases and achieve a better quality of life for patients. The business model of PYC Therapeutics focuses on partnerships, innovative developments, and scientific research that contribute to advancing the industry. PYC Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding PYC Therapeutics's Sales Figures

The sales figures of PYC Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing PYC Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize PYC Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in PYC Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about PYC Therapeutics stock

How much revenue did PYC Therapeutics generate this year?

PYC Therapeutics has achieved a revenue of 22.86 M AUD this year.

How much was the turnover of the company PYC Therapeutics compared to the previous year?

The revenue of PYC Therapeutics has increased by 43.85% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of PYC Therapeutics?

The revenue of PYC Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of PYC Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of PYC Therapeutics so important for investors?

The revenue of PYC Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does PYC Therapeutics pay?

Over the past 12 months, PYC Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PYC Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of PYC Therapeutics?

The current dividend yield of PYC Therapeutics is .

When does PYC Therapeutics pay dividends?

PYC Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PYC Therapeutics?

PYC Therapeutics paid dividends every year for the past 0 years.

What is the dividend of PYC Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is PYC Therapeutics located?

PYC Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von PYC Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PYC Therapeutics from 9/30/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did PYC Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of PYC Therapeutics in the year 2023?

In the year 2023, PYC Therapeutics distributed 0 AUD as dividends.

In which currency does PYC Therapeutics pay out the dividend?

The dividends of PYC Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von PYC Therapeutics

Our stock analysis for PYC Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PYC Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.